Thymoma is described in the packet's definition as a neoplasm arising from the epithelial cells of the thymus. According to the definition, thymomas are usually encapsulated tumors but may invade the capsule, infiltrate surrounding tissues, or metastasize to distant sites. Recognized morphologic subtypes include type A, type B (divided into B1, B2, and B3), type AB, metaplastic, micronodular, microscopic, and sclerosing thymoma. The packet lists no associated genes, and prevalence, inheritance patterns, and age of onset are not certified in this packet.

The packet lists 37 phenotype annotations, of which 16 are specified with HPO frequency labels. Chest pain, abnormal lymphocyte proliferation, abnormal lymphocyte physiology, and weight loss are annotated as frequent (30-79%). Dyspnea, abnormal mediastinum morphology, immunodeficiency, autoimmunity, decreased circulating immunoglobulin concentration, cough, night sweats, anti-neuromuscular junction acetylcholine receptor antibody positivity, neoplasm, muscle weakness, hoarse voice, and fever are annotated as occasional (5-29%). Severity and progression are not certified in this packet.

The packet lists no associated genes and no inheritance patterns, so the genetic basis and any pattern of inheritance are not certified here.

Diagnostic methods and criteria are not certified in this packet.

The packet certifies no FDA-approved treatments and no foundational therapies for thymoma. Its orphan-drug listing records several products with DESIGNATED status for thymic epithelial tumors or for thymoma and thymic carcinoma, including a PD-1-directed fusion protein sponsored by Anwita Biosciences and a bispecific PD-L1 and CTLA-4 antibody sponsored by Jiangsu Alphamab Biopharmaceuticals. Orphan designation is not FDA approval. The listing also records milciclib maleate with WITHDRAWN status for thymic epithelial tumors. Stage-specific treatment context and eligibility are not certified in this packet.

Prognosis and natural history are not certified in this packet.

According to ClinicalTrials.gov records summarized in the packet, several trials are associated with this condition. Examples with thymoma or thymic tumors in the title include NCT04417660, a Phase 2 study of bintrafusp alfa in thymoma and thymic carcinoma, sponsored by the National Cancer Institute (active, not recruiting; 2020-12-26 to 2027-07-01); NCT05104736, a Phase 2 study of PT-112 in thymoma and thymic carcinoma, sponsored by the National Cancer Institute (recruiting; 2022-04-06 to 2028-06-30); and NCT06248515, a Phase 2 study of sacituzumab govitecan in advanced thymic epithelial tumors, sponsored by Georgetown University (recruiting; 2024-04-25 to 2027-12-01). Trial titles do not establish the effect of any intervention. A ClinicalTrials.gov search link is included in the packet.